Myosin VI drives breast cancer progression via SP1/CA9-mediated acidic tumor microenvironment remodeling and subsequent M2 macrophage polarization Authors: Fang Liu, Ziyang Li, Guopeng Zeng, Shuting Yang, Ying Zhao, Fengbei Li, Zihan Yu, Zhirou Li, Jueyu Zhou Published: 2026 ABSTRACT AbstractBackgroundThe acidic tumor microenvironment (TME) is a major driver of immunosuppression and tumor progression in breast cancer. Although myosin VI (MYO6), an actin-dependent motor protein, is frequently upregulated in malignancies, its function in immune remodeling remains poorly understood.ObjectivesTo identify MYO6 as a regulator of acidic TME remodeling and macrophage polarization in breast cancer, elucidate the underlying mechanism, and evaluate its therapeutic relevance for anti-programmed death-ligand 1 (anti-PD-L1) therapy.MethodsIntegrated analyses of The Cancer Genome Atlas and Gene Expression Omnibus datasets were performed to evaluate the association of MYO6 with prognosis and M2 tumor-associated macrophage (TAM) infiltration in breast cancer. Transcriptomic, molecular, cellular, and pharmacological approaches were used to investigate MYO6-mediated acidic TME remodeling and macrophage polarization. In vivo studies assessed the effects of MYO6 inhibition by 2,4,6-triiodophenol (TIP) on tumor acidification, immunity, and anti-PD-L1 efficacy.ResultsMYO6 expression correlated with M2 TAM infiltration and poor prognosis in breast cancer. Mechanistically, nuclear MYO6 recruited SP1 and RNA polymerase II to the carbonic anhydrase 9 (CA9) promoter, upregulating CA9 and promoting acidification. The acidic TME activated the proton-sensing receptor GPR65 and the cAMP/PKA/CREB pathway in macrophages, driving M2 polarization. TIP-mediated MYO6 inhibition reduced acidification, restored antitumor immunity, and enhanced anti-PD-L1 efficacy in vivo.ConclusionMYO6 is a key molecule regulating breast cancer immune suppression and immunotherapy responsiveness. By promoting CA9-dependent extracellular acidification, MYO6 drives macrophage M2 polarization through the GPR65/cAMP/PKA/CREB pathway. Targeting MYO6 with TIP may represent a promising strategy to overcome resistance to anti-PD-L1 therapy. WHAT IS ALREADY KNOWN ON THIS TOPIC Myosin VI (MYO6) is an actin-based motor protein involved in intracellular trafficking, endocytosis, cell migration and other processes linked to tumor progression. Tumor microenvironment acidification is a well-established driver of macrophage polarization, immune suppression and resistance to immunotherapy. However, the role of MYO6 in tumor microenvironment remodeling, particularly in acidification-driven immune regulation, remains unknown. Myosin VI (MYO6) is an actin-based motor protein involved in intracellular trafficking, endocytosis, cell migration and other processes linked to tumor progression. Tumor microenvironment acidification is a well-established driver of macrophage polarization, immune suppression and resistance to immunotherapy. However, the role of MYO6 in tumor microenvironment remodeling, particularly in acidification-driven immune regulation, remains unknown. WHAT THIS STUDY ADDS This study identifies a previously unrecognized nuclear function of MYO6 in breast cancer, showing that MYO6 acts as a transcriptional scaffold for SP1 and RNA polymerase II to drive carbonic anhydrase 9 (CA9) expression and extracellular acidification. MYO6-dependent acidification activates GPR65/cAMP/PKA/CREB signaling in macrophages, promotes M2 polarization and immunosuppression, and can be therapeutically targeted to enhance immune checkpoint blockade. This study identifies a previously unrecognized nuclear function of MYO6 in breast cancer, showing that MYO6 acts as a transcriptional scaffold for SP1 and RNA polymerase II to drive carbonic anhydrase 9 (CA9) expression and extracellular acidification. MYO6-dependent acidification activates GPR65/cAMP/PKA/CREB signaling in macrophages, promotes M2 polarization and immunosuppression, and can be therapeutically targeted to enhance immune checkpoint blockade. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY These findings define the MYO6/SP1/CA9 axis as a potential immunometabolic checkpoint in breast cancer. Therapeutic targeting of this pathway, including 2,4,6-triiodophenol-mediated MYO6 inhibition or anti-programmed death-ligand 1-based combination treatment, may reverse macrophage-mediated immunosuppression and improve antitumor efficacy. Our study provides a rationale for developing combination strategies that simultaneously target tumor acidification and immune checkpoint signaling. These findings define the MYO6/SP1/CA9 axis as a potential immunometabolic checkpoint in breast cancer. Therapeutic targeting of this pathway, including 2,4,6-triiodophenol-mediated MYO6 inhibition or anti-programmed death-ligand 1-based combination treatment, may reverse macrophage-mediated immunosuppression and improve antitumor efficacy. Our study provides a rationale for developing combination strategies that simultaneously target tumor acidification and immune checkpoint signaling. Introduction Breast cancer (BC), the most prevalent female malignancy, exhibits an intricate bilateral interaction with the tumor microenvironment (TME), which can contribute to tumor progression and therapeutic resistance.1 The TME is shaped by the crosstalk between cancer cells, immune cells, fibroblasts, endothelial cells and other stromal components.2 As a principal immune component in the TME, tumor-associated macrophages (TAMs) exert a considerable influence on cancer behaviors via their interactions with cancer cells.3 TAMs exhibit functional heterogeneity, polarizing into protumor (M2-like) and antitumor (M1-like) phenotypes under different microenvironmental cues.4 The presence of M2-like TAMs in the TME promotes immune evasion and tumor progression across BC subtypes.5 Therefore, targeting TAMs including depletion, inhibition of recruitment, and reprogramming from protumorous M2 to antitumoral M1 phenotypes offers a promising strategy to improve BC treatment outcomes.6 7 Although TAMs play an indispensable role in BC progression, the underlying molecular mechanisms particularly how tumor cells recruit macrophages and promote their polarization towards the M2 phenotype are only partially understood. Tumor extracellular acidosis has emerged as a key immunometabolic feature of solid tumors. Acidic pH can suppress antitumor immune responses by impairing immune cell proliferation, cytokine production, migration, and effector functions, and strategies that neutralize tumor acidity have been proposed to improve the efficacy of cancer immunotherapy.8 9 Furthermore, it has been documented to promote macrophage polarization toward the M2 phenotype.10 This polarization is characterized by increased expression of M2 markers such as CD206, CD163 and Arg1, along with the secretion of immunosuppressive cytokines including interleukin (IL)-10 and TGF-β.11 These alterations foster an immunosuppressive milieu that enhances angiogenesis, tumor cell proliferation, invasion, and metastasis all of which are associated with poor patient prognosis.12 Myosins, a family of actin-based motor proteins, act as mechanosensors of the tumor environments and control key cellular processes linked to oncogenesis.13 Emerging evidence has underscored the pivotal role of myosins in orchestrating tumor progression and the immune microenvironment. For example, myosin II promotes immunosuppressive TAM recruitment and metastasis in melanoma,14 while MYH9 stabilization in colorectal cancer diminishes CD8+ T cell infiltration and contributes to the establishment of an immunosuppressive TME.15 Myosin VI (MYO6) is a unique minus-end-directed motor protein involved in clathrin-mediated endocytosis, intracellular trafficking and tumor development and progression.16 17 Beyond these canonical roles, MYO6 also localizes to the nucleus where it interacts with RNA polymerase II (RNAPII) to facilitate transcriptional regulation.18 However, its role in immune escape in BC remains poorly understood. In this study, we have investigated the pathogenic role of MYO6 in breast carcinogenesis and provided novel mechanistic insight into how it reshapes the tumor immune microenvironment. Our findings suggest that in BC cells, nuclear MYO6 cooperates with transcription factor SP1 and RNAPII to form a transcriptional complex that potently upregulates the expression of carbonic anhydrase 9 (CA9). This enhanced CA9 activity facilitates extracellular acidification of the TME. The acidified niche, in turn, activates the GPR65/cAMP/PKA/CREB signaling pathway in TAMs, driving their M2 polarization, thereby accelerating BC progression. In conclusion, these findings highlight a previously underappreciated role of MYO6 in modulating the acidification of TME and facilitating the polarization of M2 macrophages, which proposes a novel approach for clinical treatment. Material and methods Bioinformatics analysis In this study, The Cancer Genome Atlas (TCGA) (http://cancer genome.nih.gov), Gene Expression Omnibus (GEO) (https://www.ncbi.nlm.nih.gov/geo/), National Center for Biotechnology Information (https://www.ncbi.nlm.nih.gov/), Tumor Immune Estimation Resource 2.0 (TIMER2.0) (https://timer.comp-genomics.org/), and JASPAR (https://jaspar.elixir.no/) datasets were explored. The single-cell RNA sequencing (scRNA-seq) (GSE176078) dataset was used to analyze the distribution of GPR65, GPR68, GPR4, and GPR132 in the TME. The Kaplan-Meier plotter (https://kmplot.com/) database was used to analyze clinical features. The GEPIA2 (http://gepia2.cancer-pku.cn/) database was used to analyze the expression of MYO6. ESTIMATE algorithm and TIMER To evaluate the association between MYO6 expression and the tumor immune microenvironment, we employed two complementary computational algorithms. The Estimation of Stromal and Immune cells in Malignant Tumor tissues using Expression data (ESTIMATE) algorithm was used to calculate immune and stromal scores based on specific gene signatures, inferring the overall abundance of immune and stromal components within tumor samples. Furthermore, the TIMER2.0 web server was used to deconvolute the RNA sequencing (RNA-seq) data and quantify the infiltration levels of macrophages. Spearman’s correlation analysis was applied to assess the relationships between MYO6 expression and the various immune infiltration metrics generated by these tools. Tissue specimens and clinicopathological data A tissue microarray containing 45 paired BC tissues and adjacent non-tumor tissues was obtained from OUTDO BIOTECH (Shanghai, China). The tissue specimens were collected between May 2010 and December 2014. All cases were pathologically confirmed as BC. Adjacent non-tumor tissues were used as matched controls. The available clinicopathological information included age, tumor differentiation, tumor size, T stage, N stage, and overall clinical stage, as summarized in online supplemental table S1. The inclusion criteria were as follows: patients with pathologically confirmed BC, availability of paired tumor and adjacent non-tumor tissue specimens, and available basic clinicopathological information. Cases with incomplete tissue cores, insufficient tissue quality for immunohistochemical (IHC) evaluation, or missing essential clinicopathological information were excluded from the analysis. This cohort was used primarily for tissue-based validation of MYO6 and CA9 protein expression, CD68+GPR65+ macrophage infiltration, and for evaluating the association between MYO6 expression and clinicopathological characteristics. Complete survival follow-up data, treatment information, and clinical outcome endpoints were not available for this cohort; therefore, survival analysis and multivariate Cox regression were not performed using these clinical specimens. The detailed clinicopathological information for the cohorts provided in online supplemental table S1. Additionally, the BC datasets from GEO, GSE22093,19 GSE1456,20 21 and GSE6532,22 were used for MYO6 expression and survival analyses. These raw RNA-seq reads were subsequently analyzed using a standard RNA-seq analysis pipeline. Kaplan-Meier survival analysis Kaplan-Meier survival analysis was performed to evaluate the association between MYO6 expression and clinical outcomes in patients with BC. Overall survival (OS) analysis was conducted using the TCGA-BRCA (Breast Cancer) cohort. In addition, distant metastasis-free survival (DMFS), post-progression survival (PPS), and recurrence-free survival (RFS) were analyzed using publicly available BC datasets, including GSE22093, GSE1456, and GSE6532. Patients were divided into MYO6-high and MYO6-low expression groups according to the median expression level of MYO6 within each cohort. Survival curves were generated using the Kaplan-Meier method, and differences between groups were assessed using the log-rank test. HRs and 95% CIs were calculated using univariate Cox proportional hazards regression. A log-rank p value <0.05 was considered statistically significant. Cell lines and cell culture The following cell lines were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) (Gibco, USA) supplemented with 1% penicillin/streptomycin (Beyotime, China) and 10% fetal bovine serum (FBS, ExCell Bio, China): MCF7, T47D, SK-BR-3, JIMT-1, MDA-MB-231, MDA-MB-468, BT549, and HEK293T. MCF10A was maintained in DMEM/F12 (Gibco, USA) supplemented with 1% penicillin/streptomycin (Beyotime, China), epidermal growth factor (20 ng/mL), hydrocortisone (0.5 µg/mL), insulin (10 µg/mL), non-essential amino acids (1%) and 10% FBS (Excell). Human THP-1 monocytic cells were cultured with RPMI-1640 (Gibco, USA) supplemented with 1% penicillin/streptomycin and 10% FBS. To induce differentiation into macrophages, THP-1 cells were stimulated with 100 ng/mL phorbol 12-myristate 13-acetate (PMA, TargetMol, China) for 48 hours. All the cells were cultured at 37°C in an atmosphere containing 5% CO2. Plasmids and reagents PsPAX2, pMD2.G, and plko.1-shNC/plko.1-shMYO6/plko.1-shMyo6 plasmids were purchased from HanyiBio (Guangdong, China). VP016-U6-shNC/VP016-U6-shSP1/VP016-U6-shCA9 plasmids were purchased from GENERAL Biol (Chuzhou, China). The pcDNA3.1−3×FLAG and pGL3 promoters were purchased from Addgene. U-104, H-89, PMA and SQ22536 were bought from TargetMol (Shanghai, China). The short hairpin RNA/small interfering RNA (siRNA) targeting genes were listed in online supplemental table S4. Cell transfection MYO6 and CA9 overexpressing and empty lentiviral vectors were constructed by Hanyibio (Guangdong, China). Concentrated viruses infect 5×105 T47D and MDA-MB-468 cells in a 6-well plate. The infected cells were subsequently subjected to selection with 2 µg/mL puromycin (Beyotime, China) for 48 hours. To downregulate GPR65, siRNA (Hanyibio, Guangdong, China) was transiently transfected into THP-1 cells. In particular, when the cells were grown to 50–60% confluence, scrambled siRNA (used as the negative control)/siRNA was added to the cell culture mixture via Lipofectamine 3000 (Thermo Fisher, USA). Western blot and quantitative reverse transcription PCR (qRT-PCR) determined transfection efficiency. Differentiation of macrophages THP-1 cells were seeded in a 6/12/24-well plate and cultured with PMA (100 ng/mL) at 37°C and 5% CO2 for 48 hours to promote their differentiation into adherent macrophages. Co-culture system T47D/MDA-MB-468 cell lines and THP-1-derived macrophages were co-cultured via a cell culture insert (Corning, USA) with a 0.4 µm porous membrane to separate the upper and lower chambers. Transfected T47D/MDA-MB-468 cells (5×105 cells/well) were seeded in the upper chamber, transferred to a plate that had previously been seeded with THP-1 macrophages, and co-cultured for 48 hours. Cell-based conditional medium Tumor-conditioned medium (TCM) from T47D and MDA-MB-468 cell lines, which were subjected to MYO6 overexpression or knockdown, and fresh medium (1:1) was placed in the lower chambers of the Transwell system. For the functional study of BC cells, TCM generated from the co-culture system (upper: tumor cells with MYO6 alteration; lower: THP-1 macrophages) was added to the medium of BC cells. Cell proliferation assays For the CCK-8 assay, 1.5×103 cells/well were seeded in a 96-well plate and treated with TCM. Individually cultured tumor cells were used as controls. 10 µL of CCK-8 (Meilunbio, China) were added to each well at 0 hour, 24 hours, 48 hours, 72 hours, and 96 hours. The cells were incubated for 1 hour at 37°C, and the absorbance values were measured at 450 nm. For the colony formation assay: 1×103 cells/well were seeded in a 6-well plate and fixed for 1 hour after 14 days. Crystal violet (Beyotime, China) was added for staining overnight. Each well was subsequently washed thrice, and the number of colonies was counted via Image J software. Cell migration and invasion assay For the cell migration, 5×104 cells were suspended in 200 µL of serum-free medium, placed in the top inserts of a 24-well Transwell plate (Corning), and then exposed to TCM in the lower chambers. The cells on the bottom surface of the membrane were fixed and stained with crystal violet after 48 hours, and the cells that migrated were counted via Image J software. For the cell invasion, the membrane for the invasion assay was covered with 60 µL of Matrigel (Corning, USA) (diluted 1:8 with RPMI-1640) in advance. The tumor cells were seeded in the upper chambers; the lower chambers were filled with 500 µL TCM. After 48 hours of incubation, the cells that adhered to the lower filter surface were counted via ImageJ software. ELISA The human or mouse cAMP concentrations were determined strictly following the manufacturer’s instructions. The ELISA kit used in the study was purchased from Elabscience Biotechnology. The absorbance was measured at 450 nm. qRT-PCR Total RNA was isolated using TRIzol (Thermo Fisher, USA), and the complementary DNA was synthesized using Hifair Advance Fast SuperMix for quantitative PCR (qPCR) (Yeasen, China). Hieff qPCR SYBR Green Master Mix (Yeasen, China) was used for qRT-PCR analysis with the QuantStudio 5 system (Thermo Fisher, USA). The primers used for qPCR are listed in online supplemental table S2. The relative expression levels were analyzed compared with GAPDH, and fold changes were determined using the 2−ΔΔCt method. Western blotting Cells were collected and lysed in ice-cold RIPA lysis buffer (Yeasen, China) that contained protease and phosphatase inhibitors (Proteintech, China) for 30 min. After lysing, the supernatant was collected by centrifugation at 12,000×g for 20 min. Next, 20 µg of total protein was loaded onto 8%/10%/12% Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) gel and subsequently transferred to a 0.45 µm Polyviylidene Difluoride (PVDF) membrane (MERCK, USA). At room temperature, the PVDF membrane was blocked with 5% skim milk for 2 hours. Next, the membrane was incubated with primary antibodies overnight at 4°C. After incubation with horseradish peroxidase (HRP)-labeled secondary antibodies (Yeasen, China) at 37°C for 1 hour, the bands were detected using enhanced chemiluminescence (Thermo Fisher, USA) with the ChemiDoc MP Imaging System (Bio-Rad). The primary antibodies that were used are listed in online supplemental table S3. RNA-sequencing Total RNA from shNC and shMYO6 cells (5×106 cells, n=3 per group) was extracted using TRIzol reagent according to the manufacturer’s protocol. RNA quantity and purity were assessed using a NanoDrop spectrophotometer, and RNA integrity was evaluated using an Agilent Bioanalyzer. Only RNA samples that passed quality control were used for library construction. Poly(A) messenger RNA (mRNA) was enriched using oligo(dT) magnetic beads and used to generate sequencing libraries according to the manufacturer’s protocol. Paired-end sequencing was performed on an Illumina sequencing platform. Raw sequencing reads were subjected to quality control using FastQC. Low-quality reads and adaptor sequences were removed to obtain clean reads. Clean reads were then aligned to the human reference genome GRCh38 using HISAT2. Gene-level read counts were generated from the mapped reads using feature Counts or an equivalent read-counting tool. Differential expression analysis was performed using the DESeq2 package based on raw count data. To correct for multiple testing, p values were adjusted using the Benjamini-Hochberg false discovery rate method. Differentially expressed genes (DEGs) were defined as genes with |log₂ fold change|>1 and adjusted p value <0.05. Normalized expression values, including Fragments per Kilobase of transcript per Million mapped reads (FPKM) values, were used for data visualization, including heatmaps and expression plots. Gene Ontology (GO) enrichment analysis was performed using DEGs with significant differential expression, and enriched terms with adjusted p value <0.05 were considered statistically. Single-cell RNA-seq data processing Publicly available scRNA-seq data (GSE176078) were downloaded from the GEO database, and all available samples were included for analysis. The final dataset consisted of 27,719 genes across 100,064 cells. Gene–cell expression matrices generated after sequencing were processed in R using the Seurat package. Quality control was applied to remove low-quality cells, retaining cells with ≥200 detected genes, ≥250 Unique Molecular Identifiers (UMIs), and mitochondrial gene expression <20%. After filtering, data were normalized, highly variable genes were identified, and dimensionality reduction was performed using principal component analysis). Unsupervised clustering was conducted based on the top principal components, and cell clusters were visualized using uniform manifold approximation and projection. To correct for interpatient batch effects, Harmony was applied based on sample origin prior to clustering and visualization. Cell types were annotated according to cluster-specific DEGs and canonical marker genes, identifying tumor/epithelial cells, T cells, B cells/plasma cells, natural killer cells, myeloid cells, fibroblasts, and endothelial cells. Luciferase reporter assay T47D and MDA-MB-468 shNC/shMYO6 cells were cultured at a density of 5×104 cells/well in a 24-well plate and transfected with the dual-luciferase reporter construct pCDNA3.1-SP1, pCDNA3.1-MYO6, CA9-promoter-pGL3, and PRL-TK. Lipofectamine 3000 (Thermo Fisher, USA) was used according to the manufacturer’s instructions. Cell extracts were prepared 48 hours after transfection. The luciferase activity was measured with a Dual-Luciferase Reporter Assay Kit (Vazyme, China). Chromatin immunoprecipitation Chromatin immunoprecipitation (ChIP) was performed using the BeyoChIP Enzymatic ChIP Assay Kit (Beyotime, China) following the manufacturer’s instructions. Initially, cells were crosslinked with 1% formaldehyde and sonicated to extract and fragment chromatin. Subsequently, the samples underwent immunoprecipitation using specific antibodies. SYBR Green PCR Master Mix was used for qPCR analysis. To standardize the value of immunoprecipitated DNA, either an input signal or a control group was employed. GST pull-down assay Briefly, the coding sequence corresponding to human MYO6 amino acids 700–1253 was cloned into a His-tag expression vector, and the coding sequence corresponding to human SP1 amino acids 260–785 was cloned into a GST-tag expression vector. Recombinant MYO6-His and SP1-GST proteins were expressed in Escherichia coli and purified according to standard protocols. Purified SP1-GST protein was incubated with glutathione agarose beads at 4°C, followed by incubation with purified MYO6-His protein in binding buffer. After extensive washing to remove non-specific binding, bead-bound proteins were eluted and analyzed by SDS-PAGE and Western blotting using anti-His antibodies. GST alone was used as a negative control where applicable. Cellular thermal shift assay T47D and MDA-MB-468 cells were treated with 2,4,6-triiodophenol (TIP) or Dimethyl sulfoxide (DMSO) for the indicated time. Cells were harvested, washed with cold phosphate-buffered saline (PBS), and resuspended in PBS supplemented with protease inhibitors. The cell suspension was aliquoted equally and heated from 43℃ to 64℃ for 3 min, followed by cooling at room temperature. Cells were lysed by repeated freeze-thaw cycles or using lysis buffer, and the lysates were centrifuged to remove precipitated proteins. The soluble fractions were collected and subjected to SDS-PAGE and Western blotting. MYO6 protein levels at each temperature were detected to assess thermal stability. To evaluate relative target selectivity, the thermal stability of other myosin family members, including MYH9, and MYO1B, was examined in parallel. Immunohistochemical Tissues were fixed in 4% paraformaldehyde, embedded in paraffin, sectioned, and stained with primary antibodies. Tissue sections were subjected to antigenic repair using sodium citrate or EDTA. Non-specific binding sites on the tissue sections were blocked with 4% bovine serum albumin (BSA) (Yeasen, China). Tissues were incubated with specific primary antibodies Ki-67 (ab15580, 1:200, abcam), CA9 (ab243660, 1:200, abcam), MYO6 (26 778–1 AP, 1:200, Proteintech) overnight at 4°C. The next day, HRP-labeled secondary antibodies were added to the tissue sections. The tissue sections were stained using 3,3′-diaminobenzidine. The primary antibodies that were used are listed in online supplemental table S3. The tissue sections were stained with hematoxylin. IHC staining was reviewed and scored by two independent pathologists blinded to patients’ clinical data to quantify protein expression. Staining intensity was scored as 0 (negative), 1 (weak), 2 (moderate), and 3 (strong), while the proportion of positive cells was categorized as 0 (<5%), 1 (5–25%), 2 (26–50%), 3 (51–75%), and 4 (>75%). The final score was calculated by multiplying the intensity and proportion scores. Immunofluorescence staining The cells were fixed with 4% paraformaldehyde, permeabilized with 0.1% Triton X-100 for 10 min, and blocked with 5% BSA for 30 min. The cells were incubated with primary antibodies at 4°C overnight. Secondary antibodies were added in the dark at room temperature for 1 hour, and the cells were stained with 4,6-diamidino-2-phenylindole. Finally, the stained cells were observed and photographed using a confocal microscope (Zeiss). Fluorescence intensity and colocalization analyses were performed using the ImageJ software. Quantification of immunofluorescence staining Multiplex immunofluorescence (IF) staining was performed to detect MYO6, CD68, and GPR65 expression in tumor tissues. Images were captured under the same exposure conditions for all samples. For each case, five representative tumor fields were selected for analysis. The percentage of CD68+GPR65+ cells was quantified using ImageJ. Briefly, CD68+GPR65+ positive macrophages were identified by thresholding the corresponding fluorescence channels. Double positive CD68+GPR65+ cells were counted and expressed as a percentage of total cells or total cells. The average value from multiple fields was used as the final value for each sample. MYO6 expression was evaluated by H-score based on staining intensity and the percentage of positive tumor cells. The correlation between MYO6 H-score and the percentage of CD68+GPR65+ cells was analyzed using Spearman correlation analysis. A value of p<0.05 was considered statistically significant. Co-Immunoprecipitation assay Co-immunoprecipitation (Co-IP) assays were performed to identify interactions between different proteins. Complexes were precipitated using protein A/G magnetic beads (Yeasen, China) and Western blotting. T47D and MDA-MB-468 cell lysates were immunoprecipitated using anti-MYO6/SP1 or anti-IgG antibodies. Molecular docking AlphaFold-predicted structures of MYO6, RNAPII and SP1 were downloaded from the UniProt database (https://www.uniprot.org/). The crystal structure of MYO6 was downloaded from the RCSB Protein Data Bank (https://www.rcsb.org/). Protein–protein docking was performed using the GRAMM online server (https://gramm.compbio.ku.edu/), and the interaction force between two proteins was analyzed using the PDBePISA (https://www.ebi.ac.uk/msdsrv/prot_int/) website after obtaining the top ten docked poses. The docking simulations of MYO6, SP1, and RNAPII were predicted using the AutoDock Vina V.1.2.6 software. The MYO6 protein information was obtained from the UniProt website, and the crystal structure of MYO6 was downloaded from the RCSB Protein Data Bank. The obtained structure was imported into Discovery Studio 2019 for protein structure optimization. This process primarily involved removing water molecules, adding hydrogen atoms, assigning charges, completing missing amino acids, and repairing side chains for the protein. Finally, the optimized protein structure was obtained and exported as a PDB file. The TIP small molecule structure was acquired from the PubChem website and subjected to energy minimization using Discovery Studio 2019, after which it was saved as a PDB file. AutoDockTools V.1.5.6 was used to prepare the PDBQT files for both the protein and the small molecule. Molecular docking was then performed using AutoDock Vina V.1.2.6. Finally, visualization analysis of the docking results was conducted in PyMOL V.3.1 and Discovery Studio 2019. Flow cytometry THP-1 macrophages or bone marrow-derived macrophages (BMDMs) were co-cultured with transfected tumor cells for 48 hours. Then, these macrophages were processed into single-cell suspensions and incubated with PE-conjugated anti-human CD163 antibodies, PE/Cyanine7-conjugated anti-human CD86 antibodies, APC-conjugated anti-human CD68 antibodies, PE/Cyanine5.5-conjugated anti-mouse CD45 antibodies, FITC-conjugated anti-mouse CD11b antibodies, BV421-conjugated anti-mouse F4/80 antibodies, APC-conjugated anti-mouse CD86 antibodies, and PE-conjugated anti-mouse CD206 antibodies (BioLegend, USA) for 30 min at 4°C. Flow cytometry was performed via a flow cytometer (Beckman Coulter). Flow cytometric analysis was performed with FlowJo software (FlowJo, USA). Isolation and differentiation of BMDM BMDMs were extracted from 6–8 weeks old female C57BL/6 mice and cultured in complete DMEM medium supplemented with macrophage colony-stimulating factor (M-CSF) (20 ng/mL, BioLegend) at 37°C with 5% CO2. After 7 days, attached cells were deemed as BMDMs and collected for subsequent experiments. Isolation and differentiation of PBMC Peripheral blood samples were obtained from healthy donors with informed consent under protocols approved by the institutional ethics committee. Peripheral blood mononuclear cells (PBMCs) were isolated by density gradient centrifugation using Ficoll-Paque according to the manufacturer’s instructions. Monocytes were enriched from PBMCs by adherence culture or by CD14+ selection using magnetic beads. Purified monocytes were cultured in RPMI-1640 medium supplemented with 10% FBS, 1% penicillin-streptomycin, and human M-CSF (10 ng/mL, BioLegend) for 7 days to generate human monocyte-derived macrophages (HMDMs). Fresh medium containing M-CSF was replaced every 3 days. Differentiated HMDMs were used for subsequent co-culture experiments. Animal Tumor xenograft model Female BALB/c mice (4–5 weeks old) were purchased from the Experimental Animal Center of Guangzhou (Guangdong, China) and maintained under specific pathogen-free conditions with free access to food and water. Mice were randomly assigned to the indicated groups (n=6 per group). To determine the effect of Myo6 on tumor growth, 4T1 cells (1×106 in 100 µL PBS/Matrigel, 1:1) transduced with either vector control or OEMyo6/shMyo6 were orthotopically injected into the mammary fat pad. Tumor length and width were measured with calipers by investigators blinded to group allocation, and tumor volume was calculated as (width2×length)/2 (mm3). Mice were monitored regularly throughout the experiment, and the maximum tumor diameter did not exceed 15 mm. At day 30 after implantation, mice were deeply anesthetized and euthanized by cervical dislocation, and tumors were excised and weighed. Preparation of single-cell suspensions from tumor tissues and flow cytometry Fresh tumor tissues were collected from mice immediately after sacrifice and minced into small pieces. Tumor fragments were digested in digestion buffer containing collagenase IV (1 mg/mL), DNase I (0.2 mg/mL) at 37°C for 45 min. The digested tissues were passed through a 70 µm cell strainer to obtain single-cell suspensions. Red blood cells were lysed using red blood cell lysis buffer when necessary. Cells were washed with PBS containing 1–2% FBS. Cells were then stained with fluorochrome-conjugated antibodies against immune cell markers, including CD45, CD11b, F4/80, CD86, and CD206, according to the experimental design. Dead cells were excluded using a viability dye. Flow cytometry was performed using a flow cytometer, and data were analyzed with FlowJo software. Tail vein injection lung metastasis model 4T1 cells with stable Myo6 knockdown or overexpression, together with their corresponding control cells, were used to establish the tail vein injection lung metastasis model. Briefly, tumor cells were harvested during the logarithmic growth phase, washed with sterile PBS, and resuspended in PBS at a concentration of 1×10⁶ cells/mL. A total of 1×10⁵ cells in 100 µL PBS were injected into the lateral tail vein of each mouse (n=5 per group). Mice were monitored regularly after injection. At day 30 after implantation, mice were euthanized, and lungs were collected for assessment of metastatic burden. Lung metastatic nodules were examined macroscopically and further evaluated by H&E staining. Where applicable, metastatic burden was quantified by analyzing the metastatic area in histological sections. All animal procedures were approved by the institutional animal care and use committee and performed in accordance with relevant guidelines. In vivo macrophage depletion and pHLIP imaging To validate the polarization regulation of macrophages in vivo, clodronate (200 µL, Yeasen, China) was injected into the mice 2 days before the injection of 4T1 cells. To prevent the repopulation of macrophages, the mice were repeatedly injected with 100 µL of clodronate liposomes every 5 days. 4T1 cells (1×106 in 100 µL of PBS/Matrigel (1:1)) were injected into the mouse mammary fat pad. pHLIP imaging: on completion of the experiment, mice were subjected to tail-vein injection of 100 µL of 60 µM Cy7-labeled pHLIP peptide (N->C: AC(Cy7) DDQNPWRAYLDLLFPTDTLLLDLLW-DLys-DLys) synthesized by QYAOBIO, 6–12 hours before sacrifice. The pHLIP-Cy7 intensity for localization and distribution in non-fixed fresh tumors and major organs was imaged immediately after scarification of mice using a near-infrared fluorescent imaging system (IVIS Spectrum, PerkinElmer). Next, the tumor and organs were either fixed in 10% formalin for IF, H&E, and IHC staining. Statistical analysis Statistical analyses were conducted via the GraphPad Prism V.9.0 or R V.4.3.1 programs. The statistical results were expressed as mean±SD of at least three independent experiments for each cellular and animal group. For comparisons between two groups, unpaired two-tailed Student’s t-test was used when data were normally distributed; otherwise, a non-parametric test was applied. For comparisons among multiple groups, one-way analysis of variance followed by Tukey’s or Dunnett’s multiple comparisons test was used as appropriate. Normality and homogeneity of variance were assessed before parametric testing, respectively. The exact n values, statistical tests, and definitions of biological replicates for each experiment are provided in the corresponding figure legends. p<0.05 was considered statistically significant (in all figures: *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001; ns=not significant). Results MYO6 is highly expressed in BC and predicts poor patient prognosis To assess MYO6 expression in BC tissues, we analyzed data from the GEPIA database and paired clinical samples from the TCGA database. Compared with normal breast tissues, MYO6 mRNA levels were significantly elevated in BC tissues (figure 1A,B). Analysis of TCGA data via UALCAN revealed that elevated MYO6 expression in BC was positively correlated with advanced clinical stage and lymph node metastasis, indicating its association with disease progression (figure 1C). In addition, IHC analysis demonstrated significantly elevated protein levels in 45 cases of BC tissues compared with adjacent normal tissues (figure 1D). The associations between MYO6 and clinical characteristics were investigated in our study cohort. Notably, the tumor diameter in the high MYO6 expression group was significantly larger than that in the low expression group (p=0.042), suggesting that high MYO6 expression may be associated with increased tumor size (online supplemental table S1). However, this in-house cohort was designed for baseline clinicopathological and tissue-based validation and did not include survival follow-up information or event status. Therefore, multivariate Cox regression analysis could not be performed using this cohort. Consistently, Western blot analysis of collected tissue samples from patients with BC confirmed that MYO6 protein expression was markedly higher in BC tissues than in adjacent normal tissues (figure 1E). Meanwhile, MYO6 was highly expressed in subtypes of BC cell lines (figure 1F). Survival analysis using the Kaplan-Meier plotter revealed that high MYO6 expression was associated with significantly shorter OS, DMFS, PPS, and RFS in patients with BC (figure 1G–J). These findings indicate that MYO6 overexpression correlates with an unfavorable prognosis in BC. MYO6 is highly expressed in BC and predicts poor prognosis. (A,B) MYO6 mRNA expression levels in BC tissues and normal breast tissues from the GEPIA database (A) and paired clinical samples from the TCGA (B). (C) Comparison of MYO6 expression across BC clinical stages (Stage I–IV) and nodal metastasis status based on TCGA data analyzed via UALCAN. (D) Protein expression of MYO6 in patients with BC was detected by immunohistochemistry (adjacent tissues, n=45; tumor tissues, n=45, scale bar: 500 µm, 50 µm for Enlarge). (E) Protein expression of MYO6 in patients with BC was detected by Western blot (N, adjacent tissues; T, tumor tissues). (F) Protein expression of MYO6 in normal breast epithelial cells and different BC cells was detected by Western blot. (G–J) Kaplan-Meier survival analysis showing the correlation between high MYO6 expression and OS (F), MYO6 low expression (n=189), MYO6 high expression (n=124), DMFS (G), MYO6 low expression (n=21), MYO6 high expression (n=11), PPS (H), MYO6 low expression (n=26), MYO6 high expression (n=14), and RFS (I), MYO6 low expression (n=21), MYO6 high expression (n=48) in patients with BC. Statistical analysis was performed using two-tailed unpaired Student’s t-test (D). Significance is denoted by *p<0.05, ***p<0.001, ****p<0.0001. BC, breast cancer; DMFS, distant metastasis-free survival; mRNA, messenger RNA; MYO6, myosin VI; OS, overall survival; PPS, post-progression survival; RFS, relapse-free survival; TCGA, The Cancer Genome Atlas; TNBC, triple-negative breast cancer; TPM, transcript per million. MYO6 promotes M2-like polarization of macrophages in the TME Accumulating evidence has highlighted the involvement of myosins in tumor immunity,23 we sought to investigate whether MYO6 influences the immune landscape of BC. To assess the association between MYO6 expression and tumor immune infiltration, we applied the ESTIMATE algorithm to infer stromal and immune cell abundances in tumor tissue based on gene expression signatures, the results show that MYO6 is positively correlated with M2-type macrophages (figure 2A). These findings were further validated using the TIMER database (figure 2B). scRNA-seq data from GSE176078 indicated that MYO6 was primarily expressed in tumor cells (figure 2C,D), suggesting its potential role in indirectly modulating immune cells. In line with this, multiplex IF staining of tissue samples from patients with breast cancer revealed increased infiltration of CD163+ macrophages in tumors with high MYO6 expression (figure 2E). Similar findings were observed in orthotopic BC models in BALB/c mice (figure 2F). MYO6 promotes M2-like polarization of macrophages in the tumor microenvironment. (A–B) Correlation analysis between MYO6 expression and M2 macrophage infiltration using the ESTIMATE algorithm (A) and TIMER databases (B). (C–D) scRNA-seq analysis (GSE176078) showing the predominant expression of MYO6 in tumor cells and its distribution, ER+ (n=11), HER2+ (n=5) and TNBC (n=10). (E) Multiplex immunofluorescence staining of MYO6 and CD68+CD163+ macrophages in tissue samples from patients with breast cancer (adjacent tissues and tumor tissues, scale bar: 25 µm for Enlarge group, 50 µm for other groups, n=3). (F) Multiplex immunofluorescence staining of Myo6 and F4/80+CD206+ macrophages in shNC or shMyo6 orthotopic BC in BALB/c mice (scale bar: 25 µm for Enlarge group, 50 µm for other groups, n=3). (G) Schematic diagram of the in vitro co-culture model using PMA-differentiated THP-1 macrophages and BC cells. (H) Flow cytometry analysis showing the percentage of CD163+ macrophages after co-culture with MYO6-modified BC cells, (n=3). (I) Schematic diagram of the in vitro co-culture model using M-CSF differentiated BMDM and 4T1 cells. (J) Flow cytometry analysis showing the percentage of CD206+ macrophages after co-culture with Myo6-modified 4T1 cells, (n=3). The data presented are derived from a minimum of three independent experimental iterations and are presented as the means±SDs. Statistical analysis was performed using two-tailed unpaired Student’s t-test (H, J). Significance is denoted by ***p<0.001, ****p<0.0001. BC, breast cancer; BMDM, bone marrow-derived macrophage; DAPI, 4,6-diamidino-2-phenylindole; ESTIMATE, Estimation of Stromal and Immune cells in Malignant Tumor tissues using Expression data; M-CSF, macrophage colony-stimulating factor; MYO6, myosin VI; NK, natural killer; PMA, phorbol 12-myristate 13-acetate; scRNA-seq, single-cell RNA sequencing; TAM, tumor-associated macrophage; TIMER, Tumor Immune Estimation Resource; TNBC, triple-negative breast cancer; TPM, transcript per million; UMAP, uniform manifold approximation and projection; MSC, Mesenchymal stem cell. As shown in figure 1F, the expression of MYO6 was upregulated across all molecular subtypes of BC compared with normal mammary epithelial cells. Notably, the expression levels were higher in Luminal A and triple-negative BC (TNBC) than in the HER2-positive subtype. Clinically, Luminal A BC has the highest incidence, while TNBC is the most challenging to cure and exhibits the poorest prognosis. Given the combination of elevated MYO6 expression and clinical relevance in these two subtypes, we selected representative cell lines T47D (Luminal A) and MDA-MB-468 (TNBC) for subsequent investigations. To functionally assess its role, we established stable MYO6 overexpressing (Vector/OEMYO6) and MYO6 knockdown (shNC/shMYO6) models in T47D and MDA-MB-468 cells using a lentiviral system (online supplemental figure S1A). To examine the interactions between tumor cells and macrophages, we created an in vitro model by co-culturing BC cells with THP-1-derived macrophages differentiated by PMA (100 ng/mL) (figure 2G). Flow cytometry analysis showed that MYO6 overexpression promoted macrophage polarization toward the M2-like phenotype, indicated by an increased proportion of CD163+ cells and elevated expression of M2 markers. Conversely, MYO6 knockdown attenuated this effect (figure 2H). In contrast, MYO6 manipulation had minimal impact on M1 macrophages, as the proportion of CD86+ cells did not change significantly on either MYO6 knockdown or overexpression (online supplemental figure S1B). Further qPCR analysis of polarization markers demonstrated that MYO6 upregulated the expression of M2 markers (CD163, CD206, ARG1), while the expression levels of M1 markers (HLA-DR, CD86, iNOS) remained largely unchanged (online supplemental figure S1C and D), consistent with the flow cytometry data. To further elucidate the regulatory role of MYO6 in macrophage polarization, we isolated primary bone marrow-derived cells (BMDMs) from mice and differentiated them by induction with M-CSF (20 ng/mL) for 7 days. Meanwhile, we established stable Myo6 knockdown (shNC/shMyo6) and Myo6 overexpressing (Vector/OEMyo6) 4T1 cell lines (online supplemental figure S1E). Subsequently, these 4T1-derived shNC/shMyo6 or Vector/OEMyo6 cells were co-cultured with BMDM for 48 hours (figure 2I). After co-culture, macrophages were collected for flow cytometry analysis. Subsequent flow cytometry demonstrated that, compared with controls, CD206 expression was markedly reduced when co-cultured with shMyo6 cells and increased when co-cultured with OEMyo6 cells (figure 2J). In contrast, CD86 levels remained largely unchanged under both conditions (online supplemental figure S1F). Taken together, these results indicate that the expression of MYO6 in BC cells promotes the polarization of macrophages toward the M2-like phenotype. Based on these findings, we focused our subsequent investigations on M2-like macrophage polarization. MYO6 enhances the malignant phenotype of BC via M2-like macrophage polarization in vitro and in vivo To determine whether MYO6-driven macrophage polarization functionally contributes to tumor progression, we collected conditioned medium (TCM) from co-cultures of MYO6 modified BC cells and M0 macrophages for subsequent functional assays. CCK-8 and colony formation assays demonstrated that TCM from MYO6 overexpressing cells (OEMYO6-TCM) significantly promoted tumor cell proliferation, whereas TCM from MYO6 knockdown cells (shMYO6-TCM) suppressed it. Similarly, Transwell assays revealed that OEMYO6-TCM enhanced the migratory and invasive capacities of BC cells, an effect that was inhibited by shMYO6-TCM (online supplemental figure S2A-C). These in vitro findings indicate that MYO6 fosters a tumor-promoting microenvironment by inducing M2-like macrophage polarization. Next, we validated these findings in vivo using orthotopic mouse models (figure 3A). Myo6 knockdown significantly suppressed tumor growth, as evidenced by reduced tumor volume and tumor weight (figure 3B,C). Conversely, Myo6 overexpression accelerated tumor growth and increased both tumor volume and weight (figure 3E,F). Consistent with these observations, histopathological analysis by H&E staining and Ki67 immunohistochemistry further confirmed that Myo6 expression markedly promoted tumor cell proliferation in vivo (online supplemental figure S2D and E). We further analyzed macrophage infiltration within tumor tissues. The results showed that Myo6 knockdown markedly reduced the infiltration of CD206+ macrophages (figure 3D), whereas Myo6 overexpression increased CD206+ macrophage infiltration (figure 3G). Consistent with the in vitro findings, no obvious change was observed in CD86+ macrophage infiltration (online supplemental figure S2F). We further evaluated the effect of Myo6 on tumor metastasis using a tail vein injection lung metastasis model. The results showed that Myo6 knockout markedly reduced the pulmonary metastatic burden, whereas Myo6 overexpression increased lung metastasis (figure 3H,I). Together, these findings suggest that MYO6 not only promotes primary tumor growth but also enhances metastatic colonization in vivo. MYO6 promotes the malignant phenotype of BC through M2 phenotype macrophages in vitro and in vivo. (A) 4T1-derived shNC/shMyo6 or Vector/OEMyo6 cell lines were used for mouse mammary orthotopic tumor transplantation of BALB/c mice, (n=6). (B–C) The comparison of tumor volume and weight of the 4T1-derived shNC/shMyo6 groups. (D) Representative images and quantification of CD206+ macrophage infiltration in 4T1-derived shNC/shMyo6 groups. (E–F) The comparison of tumor volume and weight of the 4T1-derived Vector/OEMyo6 groups. (G) Representative images and quantification of CD206+ macrophage infiltration in tumor tissues of the 4T1-derived Vector/OEMyo6 groups. (H–I) Representative lung images and quantification of metastatic burden in the tail vein injection lung metastasis model, scale: 2 mm. (J) 4T1 cells were used for mouse mammary orthotopic tumor transplantation of BALB/c mice and clodronate was injected into BALB/c mice to deplete mouse macrophages (n=6). (K–L) The resulting tumors were harvested, and the tumor volume and tumor weight were measured. (M) IF staining was used to confirm the expression of CD11b+F4/80+ macrophage in the four groups of tumor samples, scale: 2 mm. (N) IHC staining was used to confirm the expression of Ki67 in the four groups of tumor samples, scale: 100 µm. The data presented are derived from a minimum of three independent experimental iterations and are presented as the means±SDs. Statistical analysis was performed using two-tailed unpaired Student’s t-test (C–D, F, and H–I) and one-way ANOVA with Tukey’s post hoc test (L–N). Significance is denoted by *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. ANOVA, analysis of variance; BC, breast cancer; DAPI, 4,6-diamidino-2-phenylindole; IF, immunofluorescence; IHC, immunohistochemical; i.p., intraperitoneal; MYO6, myosin VI; PBS, phosphate-buffered saline; TAM, tumor-associated macrophage. To specifically interrogate the role of macrophages in Myo6-mediated tumor progression, we depleted macrophages using clodronate liposomes (figure 3J). We collected mouse spleens and performed flow cytometry. The analysis revealed a significant reduction in the macrophage proportion following clodronate treatment compared with the control, confirming efficient clearance (online supplemental figure S2G). Macrophage depletion alone impeded tumor growth, and this effect was further enhanced when combined with Myo6 knockdown, resulting in the smallest tumor volumes among all groups (figure 3K,L). We further assessed macrophage presence in tumors by IF costaining for CD11b and F4/80. This analysis showed a significant reduction in macrophage infiltration following clodronate treatment, confirming efficient depletion of tumor resident macrophages (figure 3M). Immunohistochemistry has confirmed that Myo6 enhances tumor cell proliferation in vivo by affecting macrophages (figure 3N). Collectively, these results demonstrate that Myo6 promotes BC progression both in vitro and in vivo, primarily through its role in polarizing macrophages toward an M2-like phenotype. MYO6 modulates macrophage polarization by upregulating CA9 to acidify the tumor microenvironment To elucidate the mechanism by which MYO6 regulates macrophage polarization, RNA-seq was performed in shNC and shMYO6 BC cells. DEGs were identified using a threshold of |log₂FC|≥1 and p<0.05 (online supplemental figure S3A). A heatmap displayed the top 10 upregulated and downregulated DEGs on MYO6 knockdown (figure 4A). GO analyses indicated MYO6 involvement in processes such as DNA-binding transcription factor activity, extracellular space, extracellular matrix, and cargo receptor activity (figure 4B, online supplemental figure S3B). Among the DEGs, CA9 was the most markedly down-regulated gene. In T4D and MDA-MB-468 cells, CA9 expression at both mRNA and protein levels was concordantly regulated by MYO6 (online supplemental figure S3C and D). IHC staining of mouse BC tissues further confirmed that CA9 expression aligned with MYO6 levels (figure 4C, online supplemental figure S3E). Meanwhile, we performed additional analyses using our cohort of 45 human BC specimens. First, MYO6 and CA9 protein expression levels were evaluated by immunohistochemistry and quantified using H-scores. Correlation analysis using Spearman’s rank test showed a positive association between MYO6 and CA9 protein expression in BC tissues, supporting the clinical relevance of the MYO6/CA9 regulatory axis (online supplemental figure S3F). MYO6 regulates CA9 expression to modulate microenvironmental acidification and macrophage polarization. (A) Heatmap showing the top ten upregulated and downregulated DEGs identified by RNA-seq in T47D shNC versus shMYO6 cells. (B) GO enrichment analysis of cellular components for the DEGs on MYO6 knockdown. (C) IHC was used to detect the expression level of CA9 in 4T1-derived shNC/shMyo6 tumor tissues. (D) Measurement of the pH in the supernatant of MYO6 expression modification T47D or MDA-MB-468 cell cultures under the indicated conditions, (n=3). (E) 4T1-derived shNC/shMyo6 cell lines were used for mouse mammary orthotopic tumor transplantation of Balb/c mice, (n=6). (F) Intensity heat map of the ex vivo pH sensing experiment using Cy7-pHLIP. The fluorescence intensity correlates with extracellular acidity, (n=6). (G) The co-culture model of shNC/shMYO6 or Vector/OEMYO6 BC cells with M0 macrophages induced by THP-1 cells (H) Flow cytometry analysis showing the percentage of CD163+ M2 macrophages co-cultured with shNC, shMYO6, or shMYO6+CA9-overexpressing BC cells, (n=3). (I) The pH meter was used to measure the acidity value of the CM from shNC, shMYO6, or shMYO6+CA9-overexpressing BC cells, (n=3). (J) Mice were orthotopically implanted with Vector/OEMyo6 4T1 cells and treated with the CA9 inhibitor U-104 or vehicle control, (n=6). (K) Intensity heat map of the ex vivo pH sensing experiment using Cy7-pHLIP. The fluorescence intensity correlates with extracellular acidity, (n=6). (L) Representative IF images of tumor sections stained for the pan-macrophage marker F4/80 (green) and the M2 marker CD206 (red), (n=3, scale bar: 25 µm for Enlarge group, 50 µm for other groups). The data presented are derived from a minimum of three independent experimental iterations and are presented as the means±SDs. Statistical analysis was performed using two-tailed unpaired Student’s t-test (C–D and F) and one-way ANOVA with Tukey’s post hoc test (H–I and K–L). (H): T47D, F(3,8)=40.49, p<0.0001; MDA-MB-468, F(3,8)=91.56, p<0.0001. (I). T47D, F(3,8)=19.77, p<0.0005; MDA-MB-468, F(3,8)=36.87, p<0.0001. Significance is denoted by *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. ANOVA, analysis of variance; BC, breast cancer; CA9, carbonic anhydrase 9; CM, conditioned medium; DAPI, 4,6-diamidino-2-phenylindole; DEGs, differentially expressed genes; GO, Gene Ontology; IF, immunofluorescence; IHC, immunohistochemical; ip., intraperitoneal; iv., intravenous; MYO6, myosin VI; RNA-seq, RNA sequencing; TAM, tumor-associated macrophage; FOV, field of view. CA9, a cell surface enzyme, catalyzes CO₂ hydration to generate H+ and HCO₃−, and its activity has been linked to an immunosuppressive, acidic TME.24 We next assessed whether MYO6 influences extracellular acidity. Measurement of supernatant pH showed that MYO6 knockdown elevated the pH to ~7.2, while MYO6 overexpression reduced it to ~6.5 (figure 4D). Since lactic acid is a common contributor to acidosis, we quantified lactate levels by ELISA but observed no significant changes (online supplemental figure S3G). Consistent with this, Western blot analysis revealed no alterations in key lactate metabolism proteins, including LDHA, MCT1, and MCT4 (online supplemental figure S3H). To specifically evaluate CA9 dependent acidification in vivo, we then employed a pH-sensitive fluorescent probe (pHLIP-Cy7)9 in mice bearing Myo6 modified 4T1 tumors (figure 4E). Myo6 overexpression enhanced both tumor growth and fluorescence intensity, indicating stronger acidity, whereas Myo6 knockdown suppressed these effects (figure 4F, online supplemental figure S3I). Probe biodistribution analysis confirmed primary accumulation in metabolic organs, with no significant toxicity (online supplemental figure S3J). To functionally link CA9 to MYO6 driven malignancy, we performed rescue experiments (online supplemental figure S4A and B). The inhibitory effects of conditioned medium from MYO6 depleted BC cells on proliferation, migration, and invasion were all reversed by overexpressing CA9 (online supplemental figure S4C–E). Similarly, CA9 overexpression restored M2 macrophage polarization impaired by MYO6 knockdown (figure 4G,H). The increase in the pH of the culture supernatant caused by MYO6 knockdown was also restored on the re-expression of CA9 (figure 4I). We next employed the selective CA9 inhibitor U-104 (SLC-0111), which binds the zinc ion in the catalytic center to block enzymatic activity, thereby impairing its role in sustaining tumor extracellular acidification and intracellular alkalinization. To further validate the critical and necessary role of CA9 in MYO6 mediated TME acidification and macrophage M2-like polarization, we inhibited CA9 enzymatic activity using a specific CA9 inhibitor U-104 (SLC-0111) or knocked down CA9 in MYO6 overexpressing tumor cells (online supplemental figure S4G and H). We then examined the acidity of tumor cell-conditioned medium and M2 polarization of macrophages after co-culture (online supplemental figure S4I and J). The results showed that either CA9 knockdown or pharmacological inhibition of CA9 enzymatic activity reversed MYO6 overexpression-induced acidification of the TME and macrophage M2 polarization (online supplemental figure S5A and B). In vivo, U-104 treatment partially counteracted the enhanced tumor growth and acidification resulting from Myo6 overexpression (figure 4J,K, online supplemental figure S5C). IHC and IF analyses further confirmed that U-104 suppressed tumor progression and M2 polarization (figure 4L, online supplemental figure S5D). Together, these results demonstrate that MYO6 promotes BC progression by upregulating CA9, which drives extracellular acidification and subsequent M2 macrophage polarization. MYO6 transcriptionally upregulates CA9 by facilitating the assembly of the SP1-RNAPII complex Having established that MYO6 regulates CA9 expression at the mRNA level, we sought to investigate the underlying transcriptional mechanism. MYO6 is localized in both the cytoplasm and nucleus of mammalian cells (online supplemental figure S6A), and emerging evidence supports its role as a transcriptional cofactor that can interact with RNAPII to facilitate gene transcription.18 25 Given that CA9 expression is known to be transcriptionally regulated by factors such as HIF-1α (a key mediator under hypoxia) and SP1 (a critical regulator under both normoxia and mild hypoxia),26 27 we hypothesized that nuclear MYO6 might promote CA9 expression by assembling a transcriptional complex involving specific transcription factors and RNAPII. To identify the relevant transcription factor partner, we performed Co-IP and molecular docking assays. Interestingly, while MYO6 showed no detectable interaction with HIF-1α, it readily bound to SP1 and RNAPII, consistent with molecular docking predictions (figure 5A–C, online supplemental figure S6B and C). We therefore focused subsequent analyses on SP1. To further confirm the interaction between MYO6 and SP1, we constructed and expressed recombinant MYO6-His protein containing amino acids 700–1253 and SP1-GST protein containing amino acids 260–785, based on the potential interaction regions predicted by molecular docking. GST pull-down assays showed that SP1-GST successfully pulled down MYO6-His, indicating that MYO6 directly interacts with SP1 (figure 5D). IF staining revealed that MYO6 knockdown significantly reduced SP1 nuclear accumulation and its co-localization with RNAPII, whereas MYO6 overexpression enhanced both (figure 5E, online supplemental figure S6D), suggesting that MYO6 facilitates the formation of a transcriptional complex. MYO6 promotes CA9 transcription by facilitating the formation of a MYO6-SP1-RNAPII transcriptional complex. (A–B) Computational molecular docking models predicting the interaction interfaces between MYO6 and SP1 (A, left panel) and between MYO6 and RNAPII (B, right panel). (C) Co-IP assays examining the interactions between MYO6 and SP1 or RNAPII in MDA-MB-468 cell lysates. (D) GST pull-down confirmed the direct interaction between MYO6-His and SP1-GST. (E) Representative IF images showing the subcellular localization of SP1 (green) and RNAPII (red) in MDA-MB-468 shNC, shMYO6, Vector, and OEMYO6 cells, scale bar, 10 µm. (F) Dual-luciferase reporter assay measuring the activity of the CA9 promoter in shNC versus shMYO6 cells, and Vector versus OEMYO6 cells. Firefly luciferase activity was normalized to Renilla luciferase activity, (n=5). (G–H) Schematic diagram of the CA9 promoter region, illustrating the putative SP1 binding site and the location for ChIP-qPCR analysis. (I) ChIP-qPCR analysis of SP1 binding to the CA9 promoter in shNC versus shMYO6 cells, and Vector versus OEMYO6 cells, (n=5). (J) ChIP-qPCR analysis of MYO6 binding to the CA9 promoter in shNC versus shSP1 cells, (n=5). (K) Dual-luciferase reporter assay measuring the activity of the CA9 promoter in OEMYO6 versus OEMYO6+shSP1 cells. Firefly luciferase activity was normalized to Renilla luciferase activity, (n=5). The data presented are derived from a minimum of three independent experimental iterations and are presented as the means±SDs. Statistical analysis was performed using two-tailed unpaired Student’s t-test (F and I), one-way ANOVA with Dunnett’s post hoc test (J), and one-way ANOVA with Tukey’s post hoc test (K). Significance is denoted by **p<0.01, ***p<0.001, ****p<0.0001. ANOVA, analysis of variance; CA9, carbonic anhydrase 9; ChIP-qPCR, chromatin immunoprecipitation followed by quantitative PCR; Co-IP, co-immunoprecipitation; DAPI, 4,6-diamidino-2-phenylindole; IF, immunofluorescence; MYO6, myosin VI; RNAPII, RNA polymerase II; PCC, pearson correlation coefficient; TSS, transcription start site. We next examined the functional impact of MYO6 on CA9 promoter activity using a dual-luciferase reporter assay. Cotransfection of a CA9 promoter–luciferase construct with an SP1 expression plasmid in MYO6 modified cells showed that MYO6 knockdown significantly attenuated SP1-driven promoter activity, while MYO6 overexpression enhanced it (figure 5F). Furthermore, we performed ChIP followed by qPCR (ChIP-qPCR) to determine whether the MYO6/SP1 transcriptional complex was enriched at the CA9 promoter region and whether MYO6 regulated CA9 transcription by modulating SP1 promoter occupancy. First, ChIP-qPCR using an anti-SP1 antibody was performed to examine the binding of SP1 to the CA9 promoter after MYO6 knockdown or overexpression. The results showed that MYO6 knockdown markedly reduced SP1 enrichment at the CA9 promoter, whereas MYO6 overexpression enhanced SP1 occupancy at this region (figure 5G–I). These findings suggest that MYO6 facilitates the recruitment of SP1 to the CA9 promoter. To further determine whether MYO6 enrichment at the CA9 promoter depends on SP1, SP1 was knocked down in T47D and MDA-MB-468 cells, followed by ChIP-qPCR using an anti-MYO6 antibody. SP1 knockdown substantially decreased MYO6 enrichment at the CA9 promoter, indicating that SP1 is required, at least in part, for the recruitment of MYO6 to this promoter region (figure 5J). Next, to verify whether SP1 mediates the transcriptional activation of CA9 induced by MYO6, SP1 was silenced in MYO6 overexpressing cells. CA9 promoter activity, mRNA expression, and protein levels were then examined. The results demonstrated that SP1 knockdown reversed the MYO6 overexpression induced increase in CA9 promoter activity as well as CA9 mRNA and protein expression (figure 5K, online supplemental figure S6E-G). Collectively, these results indicate that nuclear MYO6 functions as a transcriptional coregulator by forming a transcriptional complex with SP1 and promoting the enrichment of SP1 and RNAPII at the CA9 promoter, thereby enhancing SP1-driven CA9 transcription and contributing to MYO6-mediated TME acidification. CA9-mediated TME acidification promotes M2 macrophage polarization via the GPR65/cAMP/PKA/CERB pathway An acidic TME is recognized to impair the function of immune cells such as macrophages and T cells, although the underlying molecular mechanisms remain incompletely understood.8 Recent studies have identified a group of proton-sensing G protein-coupled receptors (GPCRs), including GPR4, GPR65, GPR68, and GPR132, as novel pH sensors that are activated by extracellular acidification within the pH range of 6.5–7.5.28 These receptors detect pH changes via protonation of histidine residues and initiate intracellular signaling cascades. To determine which proton receptor may mediate acid-induced macrophage polarization, we analyzed scRNA-seq data of BC (GSE176078) and found that GPR65 was mainly distributed in TAM cells and had a relatively high expression level (figure 6A, online supplemental figure S7A-C). Kyoto Encyclopedia of Genes and Genomes enrichment analysis comparing GPR65+ and GPR65− macrophages revealed significant enrichment of the cAMP–PKA and TGF-β signaling pathways (figure 6B), suggesting their potential involvement in GPR65-mediated polarization. Based on the reported evidence that GPR65 activates Gαs signaling and elevates intracellular cAMP, we hypothesized that CA9-driven acidosis activates GPR65, thereby triggering cAMP accumulation, PKA activation, CREB phosphorylation, and ultimately the transcription of M2 marker genes (including CD206, ARG1, IL-10, and TGF-β). Consistently, the expression of GPR65 and the downstream cAMP/PKA/CREB signaling pathway in macrophages co-cultured with shMYO6 cells was significantly inhibited, whereas activation of this pathway was markedly enhanced in macrophages co-cultured with OEMYO6 cells (figure 6C,D). CA9-mediated TME acidification promotes M2 macrophage polarization via the GPR65/cAMP/PKA/CREB pathway. (A) Single-cell RNA sequencing dataset (GSE176078) showing the expression distribution of GPR65 across different cell types within the TME, ER+ (n=11), HER2+ (n=5) and TNBC (n=10). (B) KEGG pathway enrichment analysis of differentially expressed genes between GPR65− and GPR65+ macrophages from the dataset in (A). (C) The co-culture model of shNC/shMYO6 or Vector/OEMYO6 breast cancer cells with M0 macrophages induced by THP-1 cells. (D) Western blot and ELISA, (n=5) analyzing the GPR65/cAMP/PKA/CREB pathway. (E) THP-1 was transfected with siNC or siGPR65 and then co-cultured with breast cancer cells and Western blot or ELISA, (n=5) analysis of the GPR65/cAMP/PKA/CREB pathway. (F) Flow cytometry analysis showing the percentage of CD163+ M2-like macrophages under the (E) conditions, (n=3). (G) THP-1 was pretreated with the cAMP inhibitor SQ22536 or the PKA inhibitor H89 then co-cultured with breast cancer cells. Western blot and ELISA, (n=5) analyzing the cAMP/PKA/CREB pathway. (H) Flow cytometry analysis showing the percentage of CD163+ M2-like macrophages under the (G) conditions, (n=3). (I) The co-culture model of 4T1-derived shNC/shMyo6 or Vector/OEMyo6 cells with BMDMs. (J) Western blot and ELISA (n=5) analyzing the cAMP/PKA/CREB pathway. (K) BMDMs were pretreated with the cAMP inhibitor SQ22536 or the PKA inhibitor H89 then co-cultured with 4T1 cells. Western blot and ELISA, (n=5) analyzing the cAMP/PKA/CREB pathway. (L) Flow cytometry analysis showing the percentage of CD206+ M2 macrophages under the (K) conditions, (n=3). The data presented are derived from a minimum of three independent experimental iterations and are presented as the means±SDs. Statistical analysis was performed using two-tailed unpaired Student’s t-test (D and J) and one-way ANOVA with Dunnett’s post hoc test (F, H and K– L). (F): F(2,6)=212.2, p<0.0001; (H): F(2,6)=409.9, p<0.0001. Significance is denoted by ***p<0.001, ****p<0.0001. ANOVA, analysis of variance; BMDM, bone marrow-derived macrophage; KEGG, Kyoto Encyclopedia of Genes and Genomes; M-CSF, macrophage colony-stimulating factor; MHC, major histocompatibility complex; MYO6, myosin VI; ns, not significant; PD-1, programmed cell death protein-1; PD-L1, programmed death-ligand 1; PMA, phorbol 12-myristate 13-acetate; TAM, tumor-associated macrophage; TME, tumor microenvironment; TNBC, triple-negative breast cancer; UMAP, uniform manifold approximation and projection; BP, Biological Process; MF, Molecular Function; DMSO, Dimethyl sulfoxide; PVL, Perivascular-like cell. Rescue experiments performed in THP-1 macrophages using GPR65 siRNA showed that GPR65 knockdown abolished the co-culture-induced CREB phosphorylation and expression of the M2 marker CD163 in macrophages co-cultured with T47D or MDA-MB-468 cells (figure 6E,F, online supplemental figure S7E). Furthermore, pharmacological inhibition of cAMP (SQ22536, 10 µM) or PKA (H89, 5 µM) significantly suppressed the co-culture-induced activation of the cAMP/PKA pathway, CREB phosphorylation, and M2 macrophage polarization in macrophages co-cultured with T47D or MDA-MB-468 cells (figure 6G and H, online supplemental figure S7F), confirming the necessity of this signaling axis. To further strengthen the clinical relevance of these findings and address the need for validation in primary human macrophages, we generated HMDMs from PBMCs obtained from healthy donors (online supplemental figure S8A). HMDMs were then co-cultured with MYO6 knockdown or MYO6 overexpressing T47D and MDA-MB-468 cells. Consistent with the results observed in THP-1-derived macrophages, co-culture with MYO6 knockdown tumor cells markedly reduced GPR65 expression, cAMP/PKA/CREB pathway activation in HMDMs (online supplemental figure S8B and C). Conversely, co-culture with MYO6 overexpressing tumor cells significantly enhanced activation of this pathway in HMDMs (online supplemental figure S8B and C). Moreover, pharmacological inhibition of cAMP or PKA with SQ22536 or H89, substantially reversed MYO6 overexpression induced CREB phosphorylation and M2 marker upregulation (online supplemental figure S8D and E). These findings indicate that the GPR65/cAMP/PKA/CREB pathway also mediates CA9-associated acidification-induced M2 polarization in primary human macrophages. To further validate the necessity of this pathway, we isolated mouse BMDMs and co-cultured them with 4T1-derived shMyo6 cells or OEMyo6 cells. Macrophages harvested after co-culture were examined for activation of the cAMP/PKA/CREB pathway (figure 6I). Consistent with the results observed in THP-1-derived macrophages, co-culture with shMyo6 cells significantly suppressed the activation of this pathway, whereas co-culture with OEMyo6 cells markedly enhanced its activation (figure 6J). Concurrently, we further inhibited the cAMP/PKA pathway using H89 and SQ22536. The results showed that this treatment significantly suppressed the activation of the cAMP/PKA pathway, CREB phosphorylation, and M2 macrophage polarization in macrophages co-cultured with 4T1 cells (figure 6K,L) To further evaluate the clinical relevance of the MYO6-GPR65 axis in the BC TME in clinical specimens, 45 paired BC and adjacent non-tumor tissues and performed multiplex IF staining for MYO6, CD68, and GPR65. Compared with adjacent non-tumor tissues, BC tissues exhibited markedly higher MYO6 expression, accompanied by increased infiltration of CD68+ macrophages. Further analysis showed that the proportion of GPR65+CD68+ macrophages was significantly increased in tumors with high MYO6 expression, indicating a positive association between MYO6 expression and GPR65+ macrophage infiltration (online supplemental figure S9A and B). These findings from clinical specimens further support the notion that MYO6 may promote the enrichment of GPR65+ macrophages by regulating TME acidification. To identify cytokines secreted by M2 macrophages that promote tumor progression, we quantified the production of IL-10, TGF-β, CCL-2, and CCL-5 in M2 macrophages induced by OEMYO6-CM from T47D and MDA-MB-468 cells. Among the cytokines analyzed, IL-10 and TGF-β showed the most pronounced changes (online supplemental figure S9C). Together, these results demonstrate that CA9-mediated extracellular acidification activates GPR65 on macrophages, initiating a downstream cAMP/PKA/CREB signaling cascade that drives M2 polarization. Therapeutic targeting of MYO6 with TIP suppresses tumor growth and synergizes with anti-PD-L1 therapy TIP (also known as Bobel-24 or AM-24) is a multifaceted compound originally developed as an anti-inflammatory agent and subsequently studied for its antitumor, anti-infection, and toxicological properties29 30 (figure 7A). TIP is a pharmacological agent that perturbs MYO6 motor/ATPase related function, thereby inhibiting both its motor function and its activity as a transcriptional cofactor. Molecular docking simulations using AutoDock Vina V.1.5.6 predicted a high-affinity interaction between TIP and MYO6, with a key hydrogen bond formed at TRP1193 and a binding energy of −4.3 kcal/mol (online supplemental figure S10A). Therapeutic targeting of MYO6 with TIP inhibits tumor growth and synergizes with anti-PD-L1 therapy. (A) Structural diagram of TIP. (B) Schematic diagram of the in vivo therapeutic experiment. Mice bearing orthotopic 4T1 tumors were treated with vehicle or TIP via intraperitoneal injection every 3 days, starting a week postimplantation. (C) Representative images of excised tumors from Vehicle or TIP treatment group, (n=6). (D) Tumor volume and tumor weights from the experiment shown in (C), (n=6). (E) Representative IHC images of tumor sections stained forMyo6, Ki67, and Ca9, scale bar, 100 µm. (F–G) Representative IF images of tumor sections stained with the CD206 (red) and F4/80 (green), scale bar: 25 µm for Enlarge group, 50 µm for other groups. (H) Schematic diagram of the combination therapy experiment. Mice were treated with TIP, an anti-PD-L1 antibody, or their combination. (I) Representative images of excised tumors from each treatment group, (n=6). (J) Tumor volume and tumor weights from the experiment shown in (I), (n=6). (K) Representative IHC images of tumor sections stained for Ki67, scale bar, 100 µm. (L) Measurement of ex vivo tumor pH from resected tumors, (n=6). The data presented are derived from a minimum of three independent experimental iterations and are presented as the means±SDs. Statistical analysis was performed using two-tailed unpaired Student’s t-test (L) and one-way ANOVA with Dunnet’s post hoc test (D–E, G and J–K). Significance is denoted by *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. ANOVA, analysis of variance; DAPI, 4, 6-diamidino-2-phenylindole; IF, immunofluorescence; IHC, immunohistochemical; ip., intraperitoneal; iv., intravenous; MYO6, myosin VI; ns, not significant; PD-L1, programmed death-ligand 1; TIP, 2,4,6-triiodophenol. Given the key role of MYO6 in promoting an immunosuppressive TME, we evaluated the therapeutic potential of targeting MYO6 with TIP. In vitro, TIP treatment dose-dependently inhibited the proliferation of T47D and MDA-MB-468 cells, with IC₅₀ values of 15.69 µM, 10.72 µM, respectively (online supplemental figure S10B and C), indicating that TIP exerts a marked inhibitory effect on BC cell proliferation. To address target specificity of TIP and its potential off-target effects, we next performed a cellular thermal shift assay in TIP-treated T47D and MDA-MB-468 cells to determine whether TIP could enhance the thermal stability of MYO6. The results showed that TIP treatment markedly increased the thermal stability of MYO6 across a range of temperatures, as evidenced by reduced thermal degradation of MYO6 under high-temperature conditions (online supplemental figure S10D and G). To further assess the specificity of TIP toward MYO6, we also examined the thermal stability of two other myosin family members, MYH9 and MYO1B. In contrast to MYO6, TIP treatment did not obviously protect MYH9 (online supplemental figure S10E-H) or MYO1B (online supplemental figure S10F-I) from heat-induced degradation, and both proteins exhibited a faster degradation rate than MYO6 during thermal challenge. These findings indicate that TIP effectively binds to and stabilizes MYO6, whereas its effects on other myosin family members are relatively limited, supporting the target specificity of TIP for MYO6. Meanwhile, to further determine whether the functional effects of TIP are dependent on MYO6, we treated both control and MYO6 knockdown cells with TIP and examined CA9 expression, CA9 promoter activity, and functional changes in tumor cell–macrophage co-culture assays. Western blot and qPCR analyses showed that TIP treatment significantly reduced CA9 protein and mRNA expression (online supplemental figure S10J and K). Consistently, luciferase reporter assays demonstrated that TIP suppressed CA9 promoter activity (online supplemental figure S10L). In addition, TIP treatment attenuated tumor cell-induced M2 macrophage polarization and the associated protumor effects in the co-culture system (online supplemental figure S10M). Importantly, in MYO6 silenced cells, TIP failed to produce further additive inhibitory effects. These results suggest that the inhibitory effects of TIP on CA9 transcriptional regulation, tumor cell–macrophage interactions, and related protumor phenotypes are largely dependent on MYO6. In an orthotopic 4T1 mouse model (figure 7B), intraperitoneal administration of TIP (every third day, beginning 1 week postimplantation) led to significant, concentration-dependent suppression of tumor growth compared with the vehicle control (figure 7C,D). IHC results showed that TIP significantly reduced the expression of CA9 and Ki67 in tumors. Notably, while TIP inhibits the ATPase activity of MYO6, it did not markedly alter MYO6 protein expression in the tumors (figure 7E). TIP treatment also decreased the infiltration of CD206+ M2-like macrophages, indicating a reversal of immunosuppressive polarization (figure 7F,G). Importantly, TIP administration showed no signs of systemic toxicity, as confirmed by body weight monitoring, alanine aminotransferase/aspartate aminotransferase levels, and histopathological examination of major organs (online supplemental figure S11A and B). Since TIP reduced tumor acidity and M2-like macrophage polarization in our model, we next examined whether TIP could improve the antitumor effect of anti-programmed death-ligand 1 (anti-PD-L1) treatment. Treatment with TIP or anti-PD-L1 antibody alone resulted in a modest delay in tumor growth, whereas the combination treatment showed greater tumor growth inhibition than either monotherapy, without obvious effects on mouse body weight (figure 7H–K, online supplemental figure 11C). Consistent with our mechanistic findings, TIP treatment increased TME pH, suggesting reduced tumor acidity (figure 7L). In addition, both monotherapies decreased M2-like macrophage infiltration, and the combination treatment further reduced M2-like macrophage accumulation in tumor tissues (online supplemental figure S11D). Together, these results suggest that pharmacological perturbation of MYO6 by TIP may reduce tumor acidification and M2-like macrophage infiltration, thereby improving the antitumor effect of anti-PD-L1 treatment in this preclinical BC model. Discussion The TME is a critical regulator of cancer progression, with its acidic character, stemming from dysregulated tumor metabolism, being a key immunosuppressive feature.31 This acidosis has been reported to promote tumor-associated, immunosuppressive macrophage phenotypes, which are often operationally described as M2-like states. Our study delineates a novel mechanistic pathway in BC, our data support a model in which nuclear MYO6 acts as a transcriptional co-regulator that facilitates SP1/RNAPII associated CA9 transcription. This leads to significant acidification of the extracellular TME, which in turn activates the GPR65/cAMP/PKA/CREB signaling axis in macrophages, promoting their M2-like macrophage polarization and ultimately fostering BC progression. This cascade establishes a direct link between tumor cell-intrinsic transcription and intercellular immune reprogramming. MYO6, a unique actin-based molecular motor that moves toward the minus end of actin filaments, plays multifaceted roles in cellular processes such as vesicular trafficking, Golgi maintenance, and exocytosis.32 33 Beyond these canonical cytoplasmic functions, emerging evidence MYO6 also localizes to the nucleus, where it binds DNA via its cargo-binding domain and interacts with RNAPII through its motor domain in an actin-dependent manner.34 Both its DNA-binding capacity and ATPase activity are essential for efficient transcription in vitro.35 On transcription activation, MYO6 undergoes directed nuclear movement and anchors RNAPII at or near transcription start sites, thereby enhancing RNAPII binding and recycling to drive high-level gene expression.18 36 Although MYO6 overexpression has been linked to poor prognosis in several cancers,37 38 previous research has largely focused on its cytoplasmic roles in endocytosis, autophagy,39 and drug resistance.40 For example, MYO6 bridges GSDME-NT with the AP-2 adaptor complex to facilitate endocytosis.37 In prostate cancer, it modulates integrin beta 8 to activate focal adhesion kinase phosphorylation at tyrosine-397, promoting tumor progression and enzalutamide resistance.40 In contrast, the present study extends this understanding by revealing a significant correlation between MYO6 upregulation in BC cells and increased infiltration of M2-like TAM infiltration, pointing to a previously unexplored role for MYO6 in shaping an immunosuppressive TME. Numerous studies have highlighted the critical role of TAMs in the TME, where they contribute to tumor development and immunotherapy resistance by creating an immunosuppressive microenvironment.41 To decipher how MYO6 influences the TME, we identified CA9 as a key transcriptional target. CA9 is a hypoxia-induced enzyme anchored on the cell membrane that catalyzes the conversion of CO₂ to bicarbonate and protons, directly promoting extracellular acidification.21 Here, we demonstrated that MYO6-driven overexpression of CA9 potently enhances TME acidosis independently of lactate metabolism. The reversal of both acidification and M2-like TAM polarization on pharmacological inhibition of CA9 with U-104 firmly establishes the MYO6–CA9 axis as a critical regulator of an acidic, immune-suppressive niche in BC, extending beyond CA9’s classical role in tumorigenesis. Tumor acidosis arises from multiple sources, including glycolytic lactate production and CO₂ hydration from mitochondrial respiration and other metabolic pathways.42 43 CA9, frequently overexpressed in aggressive BC and linked to poor prognosis,44 has been associated with immune checkpoint expression and M2-like macrophage infiltration within hypoxic and acidic regions.45 Similarly, CA9 knockdown reverses TME acidosis and reprograms macrophage function in glioma.46 Our findings define a novel role for MYO6 as a critical link between metabolic remodeling and immunosuppression in the TME, where it promotes M2-like TAM polarization via CA9-dependent extracellular acidification. Although CA9 overexpression or inhibition experiments support CA9 as a major downstream mediator of MYO6-induced extracellular acidification and M2-like macrophage polarization, we cannot exclude the possibility that MYO6 may also regulate additional tumor-derived factors that contribute to macrophage reprogramming. Mechanistically, our study supports a model in which nuclear MYO6 scaffolds a specific complex with SP1 and RNAPII to activate CA9 expression. In contrast to the well-established HIF-1α–dependent pathway,47 our interaction analyses demonstrate that MYO6 specifically forms a ternary complex with the transcription factor SP1 and RNAPII, but not with HIF-1α. Recombinant protein pull-down assays confirmed a direct physical interaction between MYO6 and SP1. Mechanistically, MYO6 promoted SP1 nuclear accumulation and enhanced SP1 occupancy at the CA9 promoter, thereby increasing SP1-dependent transcriptional activation. In addition, ChIP-qPCR showed that MYO6 itself was enriched at the CA9 promoter, and this enrichment was markedly reduced on SP1 knockdown, indicating that MYO6 recruitment to the CA9 promoter is at least partly SP1-dependent. This aligns with models proposing that nuclear myosins act as molecular anchors that stabilize transcription complexes and enable high-level gene expression.48 These results uncover a non-canonical, hypoxia-independent regulatory axis in which MYO6 acts as a molecular scaffold that recruits SP1 and RNAPII to drive CA9-mediated acidification of the TME, thereby advancing our understanding of how tumor cells exploit motor protein-based transcription to shape an immunosuppressive niche. TAMs are known to adopt an immunosuppressive M2 phenotype in response to extracellular acidosis,49 yet the molecular sensors and downstream signaling pathways mediating this effect remain unclear. The sensing of acidic conditions by macrophages is mediated by a specialized class of proton-sensing GPCRs, comprising GPR4, GPR65, GPR68, and GPR132.28 50 On activation by protons, these receptors transduce signals via heterotrimeric G proteins (Gαs, Gi/o, Gq/11, and G12/13), initiating diverse downstream cascades that ultimately drive transcriptional reprogramming and phenotypic changes. We identified GPR65 as the key acid-sensing receptor in TAMs through single-cell transcriptomics, where it was uniquely highly expressed and linked to cAMP/PKA pathway enrichment. Mechanistically, extracellular protonation activates GPR65-Gαs signaling, elevating cAMP and triggering PKA-dependent CREB phosphorylation. The functional necessity of this pathway was confirmed, as both GPR65 depletion and inhibition of cAMP or PKA activity abrogated the induction of M2 markers by co-culture, underscoring the critical role of the PKA-CREB axis in acidosis-induced polarization. These findings reveal GPR65 as a crucial metabolic-immune checkpoint that links tumor cell-driven acidification to immunosuppressive polarization of TAMs, providing a mechanistically defined pathway for targeting the acidic TME in BC. We acknowledge that the classical M1/M2 framework represents an oversimplified model of macrophage polarization and does not fully capture the heterogeneity, plasticity, and spatial diversity of TAMs in vivo. This interpretation is supported by our findings in THP-1-derived macrophages, PBMC-derived primary HMDMs, mouse BMDMs, and clinical BC tissues showing increased GPR65+CD68+ macrophage infiltration in MYO6 high tumors. Nevertheless, we recognize that TAM states in human tumors are more complex than can be defined by a limited set of markers. Recent single-cell and spatial transcriptomic studies have revealed diverse TAM subsets with distinct tissue localization, transcriptional programs, and clinical significance,51 52 highlighting the need for higher-resolution profiling to define the macrophage states regulated by the MYO6/CA9/GPR65 axis. Future studies using single-cell transcriptomics, spatial profiling, and broader functional marker panels will be needed to more precisely define the macrophage subsets regulated by the MYO6/CA9/GPR65 axis and their contribution to BC progression. From a therapeutic perspective, the MYO6/CA9 axis may represent a potential vulnerability for remodeling the acidic and immunosuppressive BC microenvironment. TIP, a pharmacological agent reported to perturb MYO6 motor/ATPase-related function, reduced CA9 expression and tumor acidification in our experimental system. Such perturbation may affect MYO6-associated nuclear activities, including transcription initiation-related chromatin organization and RNAPII-dependent promoter activation.53 Consistently, TIP treatment suppressed CA9 expression, alleviated extracellular acidification, and impaired M2-like macrophage polarization in vivo. Nevertheless, we fully acknowledge the current limitations of our pharmacological characterization. In this study, it lacks formal pharmacokinetic assessments, including drug half-life, plasma concentration dynamics, and tissue distribution profiles. Since anti-PD-L1 monotherapy often shows limited efficacy, we further explored whether reducing the acidic immunosuppressive microenvironment with TIP could improve the response to anti-PD-L1 treatment. Although MYO6 inhibition enhanced the antitumor efficacy of anti-PD-L1 treatment in our mouse model. Our current data support the concept that targeting the MYO6/CA9 axis can reduce extracellular acidification and M2-like macrophage polarization, thereby remodeling an immunosuppressive TME that may be less favorable for immune checkpoint blockade. However, we did not validate this conclusion in human patients with BC receiving anti-PD-L1 therapy. Future studies using human immunotherapy cohorts, patient-derived tumor models, and longitudinal clinical specimens will be needed to determine whether MYO6 expression is associated with anti-PD-L1 response or resistance in patients. In addition, several limitations should be acknowledged. First, although our data support a nuclear transcriptional role of MYO6 in CA9 regulation, potential contributions from cytoplasmic MYO6 functions cannot be completely excluded. Second, macrophage states in tumors are highly heterogeneous, and the M2-like markers used in this study cannot fully capture the complexity of TAM phenotypes in vivo. Third, TIP showed MYO6-dependent functional effects in our system, but its complete selectivity, ATPase inhibitory activity, and pharmacokinetic profile remain to be fully characterized. Finally, our clinical cohort was relatively small and lacked survival follow-up information; therefore, the independent prognostic value of MYO6 requires validation in larger, well-annotated patient cohorts. Conclusion In conclusion, this study uncovers a MYO6/CA9/GPR65 signaling axis that connects tumor cell-intrinsic transcriptional regulation with macrophage-mediated immune remodeling in BC. Our data support a model in which nuclear MYO6 promotes SP1-dependent CA9 transcription, leading to extracellular acidification and activation of the GPR65/cAMP/PKA/CREB pathway in macrophages, thereby promoting an immunosuppressive M2-like macrophage phenotype. Pharmacological perturbation of MYO6 by TIP reduced CA9 expression, tumor acidity, and macrophage polarization, and showed greater tumor growth inhibition when combined with anti-PD-L1 treatment in a preclinical mouse model. These findings provide mechanistic insight into MYO6-mediated tumor immune crosstalk and support further investigation of the MYO6/CA9 acidification axis as a potential therapeutic target in BC. Supplementary material